Novel psychoactive substances: Shedding new lights on the ever ‐changing drug scenario and the associated health risks
(Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - June 28, 2017 Category: Psychiatry Authors: Corazza O., Parrott A.C., Demetrovics Z. Tags: EDITORIAL Source Type: research

Issue Information
No abstract is available for this article. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - June 28, 2017 Category: Psychiatry Tags: ISSUE INFORMATION Source Type: research

Fentanyl novel derivative ‐related deaths
ConclusionsThis study provides a medical–legal and toxicological assessment of this phenomenon in order to understand the role of illegal fentanyl and its congeners in deaths from FENS overdose. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - June 21, 2017 Category: Psychiatry Authors: Arianna Giorgetti, Carmela Centola, Raffaele Giorgetti Tags: SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES Source Type: research

Impact of synthetic cannabinoids on the duration of opioid ‐related withdrawal and craving among patients of addiction clinics in Kazakhstan: A prospective case–control study
DiscussionThis is the first study to assess the impact of SCs on the course of opioid withdrawal and craving symptoms. The results (a) suggest that patients with opioid use disorder in combination with regular use of SCs exhibit a significantly longer duration of opioid withdrawal and craving symptoms, (b) add to the accumulating evidence showing clinical and molecular cross talks between cannabinoids and opioids, and (c) underline novel harmful effects of SCs. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - June 20, 2017 Category: Psychiatry Authors: Mariya Prilutskaya, Francesco Saverio Bersani, Ornella Corazza, Sergey Molchanov Tags: SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES Source Type: research

The risk of violence associated with novel psychoactive substance misuse in patients presenting to acute mental health services
This report presents the initial findings of a continuing study looking into the impact of NPS misuse on admissions to an acute mental health facility in London. Violence preadmission and violence during admission have been found to be significant in NPS misusers compared to non‐NPS substance misusers. Our findings have important consequences for acute mental health, emergency, and public health services. NPS misusers require specific assessment and risk management to reduce the risk of violence towards others. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - June 19, 2017 Category: Psychiatry Authors: Abu Shafi, Paul Gallagher, Neil Stewart, Giovanni Martinotti, Ornella Corazza Tags: SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES Source Type: research

Updating of working memory in ecstasy polydrug users: Findings from fNIRS
DiscussionThe lack of a behavioural difference on both tasks but presence of blood oxygenation and deoxygenation changes in letter updating provides support for the notion that ecstasy‐polydrug users are investing more effort to achieve the same behavioural output. Total lifetime dose was high, and recency of use was significantly related to most changes, suggesting that heavy and recent use may be particularly detrimental. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - June 19, 2017 Category: Psychiatry Authors: Catharine Montgomery, John E. Fisk, Carl A. Roberts Tags: SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES Source Type: research

Novel psychoactive substance use among treatment ‐seeking opiate users: The role of life events and psychiatric symptoms
ConclusionSynthetic cathinones might still substitute amphetamine‐derivatives, although these NPS are no longer legal. There is a need for the regular screening of psychiatric symptoms and the use of family therapy among participants on opioid substitution programs. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - June 15, 2017 Category: Psychiatry Authors: M áté Kapitány‐Fövény, Judit Farkas, Patrícia Andrea Pataki, Anna Kiss, Janka Horváth, Róbert Urbán, Zsolt Demetrovics Tags: SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES Source Type: research

Pharmaco ‐toxicological effects of the novel third‐generation fluorinate synthetic cannabinoids, 5F‐ADBINACA, AB‐FUBINACA, and STS‐135 in mice. In vitro and in vivo studies
ConclusionsFor the first time, the present study demonstrates the pharmaco‐toxicological effects induced by the administration of 5F‐ADBINACA, AB‐FUBINACA, and STS‐135 in mice and suggests their possible detrimental effects on human health. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - June 9, 2017 Category: Psychiatry Authors: Isabella Canazza, Andrea Ossato, Fabrizio Vincenzi, Adolfo Gregori, Fabiana Di Rosa, Federica Nigro, Alessandro Rimessi, Paolo Pinton, Katia Varani, Pier Andrea Borea, Matteo Marti Tags: SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES Source Type: research

Oral glucose tolerance test performance in olanzapine ‐treated schizophrenia‐spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration
ConclusionsOur data suggest that BMI and triglycerides may be implicated in olanzapine‐related glucoregulatory abnormalities. The lack of correlation between glucoregulatory abnormalities and olanzapine dose or treatment duration suggests preexisting metabolic disturbances and/or disturbances arising early in the course of treatment. Clinicians prescribing antipsychotics should consider oGTT, especially in patients with obesity and/or hypertriglyceridemia. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - June 1, 2017 Category: Psychiatry Authors: Jeffrey Guina, Sayon Roy, Ankur Gupta, Daniel D. Langleben, Igor Elman Tags: RESEARCH ARTICLE Source Type: research

Hair analysis for the detection of drug use —is there potential for evasion?
ConclusionFurther research is needed by way of chemical analysis and trial of the adulterant products sold online and their effects as well as the development of more sophisticated hair testing techniques. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - May 31, 2017 Category: Psychiatry Authors: Shanna Marrinan, Andres Roman ‐Urrestarazu, Declan Naughton, Emerlinda Levari, John Collins, Robert Chilcott, Giuseppe Bersani, Ornella Corazza Tags: SPECIAL ISSUE Source Type: research

Can mobile phone technology support a rapid sharing of information on novel psychoactive substances among health and other professionals internationally?
ConclusionsThis is the right time to use mobile phone technologies for rapid information sharing and prevention activities on NPSs. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - May 31, 2017 Category: Psychiatry Authors: Pierluigi Simonato, Francesco S. Bersani, Rita Santacroce, Eduardo Cinosi, Fabrizio Schifano, Giuseppe Bersani, Giovanni Martinotti, Ornella Corazza Tags: SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES Source Type: research

Next ‐day residual effects of flibanserin on simulated driving performance in premenopausal women
ConclusionsAt both therapeutic and supratherapeutic doses, flibanserin did not impair next‐day driving performance and cognitive function compared to placebo. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - May 31, 2017 Category: Psychiatry Authors: Gary G. Kay, Thomas Hochadel, Eric Sicard, Karthi K. Natarajan, Noel N. Kim Tags: RESEARCH ARTICLE Source Type: research

Substance ‐related psychopathology and aggressiveness in a nightlife holiday resort: Results from a pilot study in a psychiatric inpatient unit in Ibiza
ConclusionsThe use of psychoactive substances was be characterised by poly‐use of both traditional and novel substances. The presence of aggressiveness emerged as a main feature associated with the use of cannabis and other cannabinoids. Binge drinking and sleep deprivation also represented a relevant component in almost all the evaluated subjects. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - May 30, 2017 Category: Psychiatry Authors: Giovanni Martinotti, Eduardo Cinosi, Rita Santacroce, Duccio Papanti, Anna Pasquini, Valerio Mancini, Mariangela Corbo, Federica Fiori, Fabiola Sarchione, Daniela Marchetti, Maria Cristina Verrocchio, Massimo Di Giannantonio, Marta Torrens, Fabrizio Schif Tags: SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES Source Type: research

Novel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders: A multicenter ‐observational study
ConclusionsThe use of NPS in a young psychiatric population appears to be frequent, and probably still underestimated. Bipolar disorder shows an association with NPS use. Careful and constant monitoring and an accurate evaluation of possible clinical effects related to NPS use are necessary. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - May 18, 2017 Category: Psychiatry Authors: Tiziano Acciavatti, Matteo Lupi, Rita Santacroce, Andrea Aguglia, Luigi Attademo, Laura Bandini, Paola Ciambrone, Giulia Lisi, Giovanni Migliarese, Federica Pinna, Diego Quattrone, Michele Ribolsi, Maria Salvina Signorelli, Salvatore Cal ò, Fabrizio Schi Tags: SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES Source Type: research

Genie in a blotter: A comparative study of LSD and LSD analogues' effects and user profile
ConclusionsLSD analogues were reported as similar in time to peak and duration as LSD but weaker in strength, pleasurable high, and comedown. Future studies should seek to replicate these findings with chemical confirmation and dose measurement. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - May 18, 2017 Category: Psychiatry Authors: Leigh D. Coney, Larissa J. Maier, Jason A. Ferris, Adam R. Winstock, Monica J. Barratt Tags: SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES Source Type: research